Sotyktu Demonstrates Durable Response Rates, Consistent Safety in Moderate-to-Severe Plaque PsO
Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. Week 208 responses for Psoriasis Area and Severity Index (PASI) 75 and 90 were 71.7% and 47.5%, respectively, and 57.2% […]